Navigation Links
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Date:12/4/2007

proceed to Phase I clinical trials by the end of 2007. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

For further information please contact:

ThromboGenics

Prof. Desire Collen, CEO

Dr. Patrik De Haes, COO

Tel: +32(0)16-34-61-94

Citigate Dewe Rogerson

Valerie Auffray / David Dible / Amber Bielecka

Tel: +44(0)207-638-95-71

valerie.auffray@citigatedr.co.uk


'/>"/>
SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready for ... The Innovation Center @3401 , a collaborative effort of ... to help attract and nurture start-up businesses in the ... , The Innovation Center @3401 (ic@3401), which is ... the new home of DreamIt Ventures and ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
(Date:7/29/2014)... 2014 Dr. Jason Wendel – recipient of ... one of the Top 10 Plastic Surgeon Specialists for Nashville, ... products. His complete line includes a Hydration Booster, Retexturing Night ... face and skin a younger, more radiant appearance while protecting ... is different, that is why at Dr. J. J. Wendel ...
(Date:7/28/2014)... DIEGO , July 28, 2014 ... cultivation technologies, today announced the appointment of biotechnology veteran ... of the board of directors. Levine replaces Cynthia ,CJ, ... immediately. She will remain chairman of the company,s board ... on Sapphire Energy,s mission to deliver commercial scale algae-based ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... Rice University,s award-winning undergraduate summer research program NanoJapan ... $4 million grant from the National Science Foundation ... from all U.S. universities, combines a traditional study-abroad ... internship in nanotechnology. The program was created in ...
... Sept. 21 Oxford Resource Partners, LP (NYSE: ... today announced their collaborative agreement to develop a pilot ... previously reclaimed from mining operations by Oxford. The goal ... economic viability of biomass production from dedicated energy crops ...
... JERUSALEM, Sept. 21 Chiasma, Inc., a privately ... CEO, will present an overview of the Company at the ... York, New York, on Wednesday, September 22, 2010 at 11:00 ... clinical trial of the investigational new drug Octreolin™, an oral ...
Cached Biology Technology:Rice University's award-winning NanoJapan program wins $4M grant 2Rice University's award-winning NanoJapan program wins $4M grant 3Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio 2Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio 3Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio 4Chiasma to Present at the UBS Global Life Sciences Conference 2Chiasma to Present at the UBS Global Life Sciences Conference 3
(Date:7/29/2014)... bacteria and algae, propel themselves using whip-like appendages ... a millimetre long, function like tiny oars, helping ... cilia are found on the surfaces of many ... liquids over the cell. , Flagella and ... expel pathogens from our airways, they establish the ...
(Date:7/28/2014)... by the U.S. Food and Drug Administration (FDA) for ... bacterial pathogens inside human cells, including those that cause ... published in mBio , the online open-access journal ... way of identifying non-antibiotic drugs that could one day ... drugs on the list inhibit the growth of at ...
(Date:7/28/2014)... reached the South Pole in 1911, but new research ... human. , Using data from 16 ice cores collected ... the South Pole, a group led by Joe McConnell ... created the most accurate and precise reconstruction to date ... record, described in an article published today in the ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... ranging from the shellfish Swedish people eat at traditional ... their millions in both freshwater and saltwater. One of ... crustacean to have its genome sequenced. A researcher from ... The sequencing has been done in an international ...
... of cancer deaths resulted from metastasis, the spread of ... exploration of the possible mechanical factors that promote metastasis ... is expanding the scientific understanding of what makes malignant ... fibrous matrix that surrounds cancer cells. Karen ...
... SPRING HARBOR, N.Y. (March 22, 2011) - An ... to scientists and nonscientists alike. Its behavior involves processes ... those external to itenvironment and social surroundings. According to ... tapestry of biology: It is sparked when neurons fire ...
Cached Biology News:Surprising results in the first genome sequencing of a crustacean 2WSU proves extracellular matrix tugging creates come hither stimulus for cancer migration 2New book on animal behavior provides integrated view 2
Request Info...
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
... I from E. coli is ... enzyme also contains both 5'--3'and ... exonuclease activity enables the enzyme ... in the DNA as starting ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
Biology Products: